Martine A. Rothblatt, who serves as chairperson and chief executive officer of United Therapeutics Corp (NASDAQ:UTHR), executed a sale of 9,500 shares of the company's common stock on July 7, 2026. The transaction resulted in proceeds of approximately $5.31 million. The shares were sold at prices ranging from $553.1161 to $563.2381 per share.
These sales followed the exercise of 9,500 stock options by Ms. Rothblatt on the same day. The options were exercised at a price of $135.42 per share, totaling approximately $1.29 million. The transaction comes as United Therapeutics shares have surged 91% over the past year, currently trading at $554.70. According to InvestingPro analysis, the stock is trading above its Fair Value, placing it among overvalued equities. The company maintains an impressive gross profit margin of 86.58% and holds more cash than debt on its balance sheet.
Both the exercise of stock options and the subsequent sale of common stock were conducted under a pre-arranged 10b5-1 trading plan. This plan was adopted by Ms. Rothblatt on November 7, 2025, and is set to continue until either 1,734,410 stock options are exercised (all of which expire on March 15, 2027) or December 31, 2026, whichever comes first.
Following these transactions, Ms. Rothblatt directly holds 40,513 shares of United Therapeutics common stock. Additionally, she holds indirect ownership through various family trusts and a spouse, which collectively account for 628,215 shares. Stock options representing 349,192 underlying shares are also held indirectly in a family trust.
In other recent news, United Therapeutics Corporation has received premarket approval from the U.S. Food and Drug Administration for its LungFX device, designed for centralized ex vivo lung perfusion. This device is intended to assess donor lungs outside the body, enhancing the evaluation process before transplantation. Additionally, United Therapeutics announced that its TETON-1 phase 3 study of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint. The study showed that Tyvaso preserved lung function and reduced the risk of clinical worsening events, with results published in the New England Journal of Medicine.
In the realm of partnerships, United Therapeutics has teamed up with Varda Space Industries to explore microgravity-based pharmaceutical processing. This collaboration aims to improve the stability and bioavailability of treatments targeting rare pulmonary diseases through missions to low Earth orbit. Furthermore, TD Cowen has reiterated a Buy rating for United Therapeutics stock, maintaining a price target of $675.00. These developments highlight the company's ongoing advancements in both medical technology and strategic partnerships.